Teva's celiac antibody met Phase 2a goals, Allergic Living reports. Here's what the results mean for patients and families, and how far there is still to go.
A new review identifies exosomes as key players in celiac disease, with potential as non-invasive biomarkers for diagnosis and targets for new treatments.
A newly engineered enzyme called celiacase degrades immunogenic gluten peptides by up to 99% in lab tests, offering hope as a therapeutic adjunct to the gluten-free diet.
An experimental drug shows promise for treating celiac disease beyond the gluten-free diet. What celiac families should know about this development.